TheranosticTrials.org

Clinical Trial · NCT06560905

Preoperative Planning With PSMA-PET in Melanoma Surgery Trial

Overview

This is a non-randomised, single-centre Phase 2 study, investigating whether the diagnostic biomarker, prostate-specific membrane antigen (PSMA), can detect melanoma metastases using PSMA PET/ CT.

Sponsor

Royal Marsden NHS Foundation Trust

Phase

Phase 2

Contacts

Reyhaneh Sadegh Zadeh (CONTACT)

reyhaneh.sadeghzadeh@rmh.nhs.uk

020 7352 8171

Myles Smith (PRINCIPAL_INVESTIGATOR)

ClinicalTrials.gov

NCT06560905

Drug / Compound

PSMA

Isotope(s):
Target(s):
  • PSMA
Ligand Class: Small Molecules
Chelator: HBED-CC

Eligibility

Inclusion

Inclusion criteria not yet provided.

Exclusion

  • Patients not willing to complete all the study assessments
  • Patients who are females
  • Patients who have had Lu-177 PSMA therapy or barium studies within a period of 10 days prior to undergoing PSMA PET-CT scanning
  • Patients not fluent in English
  • Patients who are taking androgen deprivation therapy (ADT) and other therapies targeting the androgen pathway, such as androgen receptor antagonists.
  • Patients who have or have previously been diagnosed with prostate cancer